Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
As part of the celebrations, the Institute organised a series of activities in the run up to International Nurses Day which is observed on 12th May every year
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The partners also aim to expand their work to Latin America for the first time
Subscribe To Our Newsletter & Stay Updated
